<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "dabrafenib cap>
<dose><value>150</value>
<value>100</value>
<value>50</value>
<value>75</value>
</dose><route><value>PO</value>
</route><form><value>cap</value>
</form><drugname><value>dabrafenib cap</value>
</drugname><strength><value>50 mg</value>
<value>75 mg</value>
</strength><frequency><value>BID</value>
</frequency><instruction><value></value>
</instruction><volume><value></value>
</volume><units><value>mg</value>
</units><additionalnotes><value>Dose level reductions: First reduction: 100 mg PO BID. Second reduction: 75 mg PO BID. Third reduction: 50 mg PO BID. If unable to tolerate 50 mg BID, recommend discontinuing dabrafenib. In clinical studies, patients 65 years of age and older experienced more serious adverse effects when taking dabrafenib.</value>
</additionalnotes><population><value></value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=7302</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=7303</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>